NCT01363934 - To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Healthy Volunteer

Interventions

DRUG

GC1113

"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."

DRUG

Darbepoetin alfa

Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.